To examine socioeconomic, demographic, and behavioural factors that influence the incidence of methylphenidate use among children aged 4 to 13 years.
Method:
A total of 11 316 children, aged 2 through 11 years, from Cycle 1 (1994–95) of the National Longitudinal Survey of Children and Youth were followed up 2 years later in Cycle 2 (1996–97). The outcome measure was methylphenidate use in Cycle 2. Individual-level explanatory variables included sex, age, socioeconomic status (SES), mother's age at birth of child, lone-parent family status, parental working status, and hyperactivity-impulsivity and inattention probabilities. Area-level explanatory variables included income and rural or urban residence. We used hierarchical linear modelling to examine individual- and area-level factors that predicted methylphenidate use.
Results:
The strongest predictors of methylphenidate use were behavioural: children with high hyperactive-impulsive and (or) inattention behaviours in 1994, compared with children low on these behaviours, were 4.5 to 6 times more likely to use methylphenidate 2 years later. SES remained a significant predictor of the incidence of methylphenidate use, even when other significant predictors were held constant, with lower SES being associated with higher use. Area-level income also predicted methylphenidate use.
Conclusion:
Even when children with similar behavioural symptoms and demographic characteristics were compared, socioeconomic factors had a significant impact on incidence of methylphenidate use.
SzatmariPOffordDRBoyleMH. Ontario Child Health Study: Prevalence of attention deficit disorder with hyperactivity. J Child Psychol Psychiatry1989;30:219–30.
2.
BarkleyRADuPaulGJMcMurrayMB. Comprehensive evaluation of attention deficit disorder with and without hyperactivity as defined by research criteria. J Consult Clin Psychol1990;58:775–89.
3.
BiedermanJFaraoneSMilbergerSGuiteJMickEChenL, and others. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry1996;53:437–46.
4.
LaheyBBPelhamWESteinMALoneyJTrapaniCNugentKKippHSchmidtELeeSCaleMGoldEHartungCMWillcuttEBaumannB.Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children. J Am Acad Child Adolesc Psychiatry1998;37: 695–702.
5.
BrownellMDYogendranM.Attention-deficit hyperactivity disorder in Manitoba children: Medical diagnosis and psychostimulant treatment rates. Can J Psychiatry2001;46:264–72.
6.
LeFeverGBDawsonKVMorrowAL. The extent of drug therapy for attention-deficit/hyperactivity disorder among children in public schools. Am J Public Health1999;89:1359–64.
7.
ZitoJMSaferDJdos ReisSGardnerJFBolesMLynchF.Trends in the prescribing of psychotropic medications to preschoolers. JAMA2000;283:1025–30.
8.
KlassenAMillerARainaPLeeSKOlsenL.Attention-deficit hyperactivity disorder in children and youth: A quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry1999;44:1007–16.
9.
National Institutes of Health Consensus Development Conference Statement: Diagnosis and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry2000;39:182–93.
10.
SchachterHMPhamBKingJLangfordSMoherD.How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ2001;165:1475–88.
11.
The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry1999;56:1073–86.
12.
The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics2004;113:754–61.
13.
MillerARLalondeCEMcGrailKMArmstrongRW. Prescription of methylphenidate to children and youth, 1990–1996. CMAJ2001;165:1489–94.
14.
RappleyMDGardinerJCJettonJRHouangRT. The use of methylphenidate in Michigan. Arch Pediatr Med1995;149:675–9.
15.
ReidRHakendorfPProsserB.Use of psychostimulant medication for ADHD in South Australia. J Am Acad Child Adolesc Psychiatry2002;41:906–13.
16.
ZitoJMSaferDJDosReisSGardnerJFMagderLSoekenKBolesMLynchFRiddleMA. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med2003;157(1):17–25.
17.
HarelEHBrownWD. Attention deficit hyperactivity disorder in elementary school children in Rhode Island: Associated psychosocial factors and medications used. Clin Pediatr2003;42:497–503.
18.
ScahillLSchwab-StoneM.Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am1999;9:541–55.
19.
St. SauverJLBarbaresiWJKatusicSKColliganRCWeaverALJacobsenSJ. Early life risk factors for attention-deficit/hyperactivity disorder: A population-based cohort study. Mayo Clin Proc2004;79:1124–31.
20.
SzatmariP.The epidemiology of attention-deficity dyperactivity disorders. Child Adolesc Psychiatr Clin N Am1992;1:361–71.
21.
RieppiRGreenhillLLFordREChuangSWuMDaviewM, and others. Socioeconomic status as a moderator of ADHD treatment outcomes. J Am Acad Child Adolesc Psychiatry2002;41:269–77.
22.
SaferDJKragerJM. A survey of medication treatment for hyperactive/inattentive students. JAMA1988;260:2256–8.
23.
BussingRZimaBTGaryFAGarvanCW. Barriers to detection, help-seeking, and service use for children with ADHD symptoms. J Behav Health Serv Res2003;30:176–89.
24.
DillerLH. Running on methylphenidate: A physician reflects on children, society and performance in a pill. New York (NY): Bantam Books; 1998.
25.
JensenPSKettleLRoperMTSloanMTDulcanMKHovenC, and others. Are stimulants overprescribed? Treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry1999;38:797–804.
26.
Statistics Canada, 2005. National Longitudinal Survey of Children and Youth (NLSCY): Cycle 1, 1994–95. Available: www.statcan.ca/english/rdc/nlscy_cycle1.htm. Accessed 2006 Aug 24.
27.
Statistics Canada, 2005. National Longitudinal Survey of Children and Youth (NLSCY): Cycle 2, 1996–97. Available: www.statcan.ca/english/rdc/nlscy_cycle2.htm. Accessed 2006 Aug 24.
28.
Human Resources Development Canada, 1996. National Longitudinal Survey of Children and Youth (NLSCY): Overview Report. Available: www11.hrdc-drhc.gc.ca/pls/edd/NLSCY.lhtml. Accessed 2006 Aug 24.
RomanoEBaillargeonRHTremblayRE. Prevalence of hyperactivity-impulsivity and inattention among Canadian children: Findings from the first data collection cycle (1994–1995) of the National Longitudinal Survey of Children and Youth. Hull (QC): Applied Research Branch, Human Resources and Development Canada; 2002.
31.
RindskopfDRindskopfW.The value of latent class analysis in medical diagnosis. Stat Med1986;5:21–7.
RaudenbushSWBrykAS. Hierarchical linear models: Applications and data analysis methods. 2nd ed. Advanced quantitative techniques in the social sciences: Volume 1. Thousand Oaks (CA): Sage Publications, Inc; 2002.
34.
ZhangJYuKF. What's the relative risk: A method of correcting the odds ratio in cohort studies of common outcomes. JAMA1998;280:1690–1.
35.
DooleyMDCurtisLLipmanELFeenyDH. Child psychiatric disorders, poor school performance and social problems: The roles of family structure and low-income. In: CorakM, editor. Labour markets, social institutions and future of Canada's children. Ottawa (ON): Statistics Canada; 1998. (Cat. nr 89–553-XIB).
36.
SzatmariPOffordDRBoyleMH. Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder: Findings from the Ontario Child Health Study. J Child Psychol Psychiatry1989;30:205–17.
37.
RappleyMDEneliIUMullanPBAlvarezFJWandJLuoZ, and others. Patterns of psychotropic medication use in very young children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr2002;23(1):23–30.
38.
Brooks-GunnJDuncanGJ. The effects of poverty on children. Future Child1997;7(2):55–71.
